Galena Biopharma, Inc., a biopharmaceutical company focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company’s peptide vaccine immunotherapies utilize the patient’s own immune system to identify and destroy cancer cells. Enhanced by multiple development and commercial collaborations, the company’s suite of immunotherapeutic solutions is poised to capitalize on the vast opportunities in today’s healthcare industry.
Seeking Alpha yesterday published the following article featuring GALE: http://seekingalpha.com/article/1610482
The article titled “Galena Biopharma Presents an Attractive Investment Opportunity” offers a brief overview of Galena management and takes into consideration the company’s science, technical status, fundamentals and future catalysts for upcoming growth.
Looking at the stock’s one-year chart shows a gain of more than 37 percent in the last 52 weeks, reversing a recent downturn. The stock’s performance outpaced the healthcare and broader market-related ETFs. To compare, the Healthcare ETF has increased by roughly 33 percent over the last year while S&P 500 ETF has risen 22 percent for the same period.
Galena’s attractive drug pipeline demonstrates its opportunities for growth and generating revenues. In addition to its upcoming launch of the company’s FDA-approved cancer pain treatment, Abstral, Galena is continuing to develop NeuVax for the treatment of breast cancer.
In late 2012, Galena signed an agreement with Teva Pharmaceuticals (TEVA) to commercialize NeuVax in the country of Israel, freeing Galena to focus on the actual trials and save available cash since the agreement calls for Teva to fund commercialization. As part of the deal, shareholders can expect to see a large royalty on any NeuVax sales that occur in Israel.
The article also points to Galena’s financial standing. As of May 13, 2013, Galena had approximately $30.2 million available cash and approximately $10 million of long-term debt. With a burn rate of $1.25 million per month, cash on hand will likely run low in the second half of 2014, though Galena expects to earn up to $3 million this year and between $8 million – $12 million in 2014 upon success of the launch of Abstral.
For more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
